Mark Maire Appointed CEO of Rebion
Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer.
Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVision Systems to Alcon, and the expansion of surgical imaging solutions at Cassini Technologies.
As CEO, Mr. Maire will lead Rebion's next phase of growth, with an immediate focus on advancing the company’s Traq platform through the FDA approval process, scaling commercial adoption of its flagship Blinq device, and positioning the company for strategic partnerships and long-term value creation.
“Mark is the right leader at the right time,” said David Hunter, MD, PhD, co-founder and Chairman of Rebion’s Board. “His ability to guide transformational technologies from concept to clinic is exactly what Rebion needs. His experience across commercial operations, strategic sales, and acquisitions makes him uniquely qualified to lead us into this next chapter.”
Mr. Maire most recently served as CEO of Cassini Technologies, where he spearheaded the evolution of its corneal diagnostics platform into a cloud-based solution for surgical planning and intraoperative guidance. Priviously, he was Chief Revenue Officer at TrueVision Systems, where he led global commercial growth and directed the M&A process resulting in the company’s acquisition by Alcon in 2018. Following the acquisition, he spent 3 years with Alcon as a surgical consultant, working closely with ophthalmic surgeons and clinical teams across the US. Mr. Maire also serves on the board of LaunchPoint, an aerospace company specializing in propulsion systems.
“This is a mission I believe in deeply,” Mr.Maire said. “Rebion’s technology represents a step-change in how we diagnose and monitor neurologic and visual disorders. Using polarized light and retinal scanning, we can uncover biomarkers that were previously invisible. I’m honored to lead this team and committed to delivering meaningful clinical and commercial outcomes.”
Rebion’s proprietary platform uses polarized light-based retinal scanning to measure neurological function with precision and objectivity. Its FDA-cleared Blinq device is designed to enable early, noninvasive detection of amblyopia and strabismus in children. Traq, which is currently under development, is designed to expand Rebion’s diagnostic reach into traumatic brain injury, dementia, and other neurodegenerative conditions.